Bebtelovimab is a human IgG1κ monoclonal antibody targeted against the spike protein of SARS-CoV-2 which is used in the treatment of mild-to-moderate COVID-19. It binds to a portion of the SARS-CoV-2 spike (S) protein's receptor-binding domain, thereby preventing spike protein interaction with ACE2 and subsequent viral entry into host cells.
- Mechanism
- Curator reviewed · 4 references
Bebtelovimab is a neutralizing human IgG1κ monoclonal antibody targeted against the spike (S) protein of SARS-CoV-2, which is responsible for facilitating viral entry into host cells. More specifically, bebtelovimab binds to an epitope of the S protein receptor-binding domain (RBD) which overlaps the ACE2-interacting site, effectively inhibiting the interaction between ACE2 and the S protein required for viral entry.
Of note, the epitope to which bebtelovimab binds is infrequently mutated, making it theoretically less susceptible to viral resistance. In vitro studies using a number of variants of concern (VOCs) demonstrated retained activity across all variants tested, including the newer and highly infectious B.1.1.529 (Omicron) variant.
- Primary indication
- Bebtelovimab currently has no approved indications.Curator reviewed
- Formula / weight
- 144000.0 Da
- Code names
- LY-3853113 · LY-COV1404
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with Bebtelovimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account